文献速递骨软组织肉瘤与黑色素瘤

帕唑帕尼或甲氨蝶呤-长春花碱联合化疗治疗成人进展性硬纤维瘤(DESMOPAZ):非比较、随机、开放标签、多中心、2期研究

Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
PubMed 文献 · Lancet Oncol · 2019-07-19

DESMOPAZ是一项非比较、随机、开放标签、多中心2期试验,纳入72例进展性硬纤维瘤成人患者,随机(2:1)接受帕唑帕尼或甲氨蝶呤-长春花碱联合化疗。帕唑帕尼在进展性硬纤维瘤中具有临床活性,可能成为该罕见致残性疾病的有效治疗选择。

要点

  • 帕唑帕尼组最常见3/4级不良事件为高血压(21%)和腹泻(15%)。

核心结论

  • 帕唑帕尼在进展性硬纤维瘤患者中具有临床活性,可能成为该罕见致残性疾病的有效治疗选择。

研究设计与样本

  • DESMOPAZ为法国肉瘤组12个中心开展的非比较、随机、开放标签、2期试验。
  • 纳入≥18岁、器官功能正常、经中心文档确认的进展性硬纤维瘤成人患者,随机(2:1)分配至口服帕唑帕尼800 mg/日(最长1年)或静脉甲氨蝶呤-长春花碱联合化疗。
  • 主要终点为帕唑帕尼组前43例接受1个完整或2个不完整周期治疗的患者6个月无进展比例;甲氨蝶呤-长春花碱组同一终点作为预设探索性终点评估。

主要发现

  • 帕唑帕尼组46例、甲氨蝶呤-长春花碱组20例可评估 activity。

关键数值与推荐

  • 帕唑帕尼组最常见3/4级不良事件为高血压(n=10,21%)和腹泻(n=7,15%)。
  • 甲氨蝶呤-长春花碱组最常见3/4级不良事件为中性粒细胞减少(n=10,45%)和肝转氨酶升高(n=4,18%)。
  • 帕唑帕尼组11例(23%)发生至少1件与研究治疗相关的严重不良事件,甲氨蝶呤-长春花碱组6例(27%)。

临床怎么用

  • 帕唑帕尼可作为进展性硬纤维瘤的一种治疗选择,尤其适用于需要系统治疗的患者。
  • 治疗期间需监测高血压和腹泻等不良反应。

局限性

  • 本研究为非比较、随机、开放标签设计,样本量较小(共72例)。
  • 主要终点仅在帕唑帕尼组前43例可评估患者中评估,甲氨蝶呤-长春花碱组同一终点为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Desmoid tumours are locally aggressive tumours associated with substantial morbidity. No systemic treatments are approved for this disease, with methotrexate-vinblastine the only chemotherapy regimen assessed in a clinical trial setting to date. VEGF overexpression is a common feature in aggressive desmoid tumours. Pazopanib is an oral antiangiogenic agent targeting VEGF receptors 1, 2, and 3, platelet-derived growth factor receptor-like protein (PDGFR) α and β, and c-KIT tyrosine kinases. We aimed to assess antitumour activity and safety of targeted therapy or combination chemotherapy in progressive desmoid tumours. METHODS: DESMOPAZ was a non-comparative, randomised, open-label, phase 2 trial conducted at 12 centres from the French Sarcoma Group. We enrolled adults (≥18 years) with progressive desmoid tumours, normal organ function and centrally documented progressive disease according to Response Evaluation Criteria in Solid Tumors version 1.1 based on two imaging assessments obtained within less than a 6-month interval. Participants were randomly assigned (2:1) to oral pazopanib 800 mg per day for up to 1 year or to an intravenous regimen combining vinblastine (5 mg/m2 per dose) and methotrexate (30 mg/m2 per dose), administered weekly for 6 months and then every other week for 6 months. Randomisation was stratified according to inclusion centre and tumour location. The primary endpoint was the proportion of patients who had not progressed at 6 months in the first 43 patients who had received one complete or two incomplete cycles of pazopanib. This endpoint was also assessed as a prespecified exploratory endpoint in all patients who had received one complete or two incomplete cycles of methotrexate-vinblastane. Safety analyses were done for all patients who received at least one dose of allocated treatment. This trial was registered with ClinicalTrials.gov, number NCT01876082. FINDINGS: From Dec 4, 2012, to Aug 18, 2017, 72 patients were enrolled and randomly assigned (n=48 in the pazopanib group; n=24 in the methotrexate-vinblastine group). Median follow-up was 23·4 months (IQR 17·1-25·5). 46 patients in the pazopanib group and 20 patients in the methotrexate-vinblastine group were assessable for activity. In the first 43 patients assessable for the primary endpoint in the pazopanib group, the proportion of patients who had not progressed at 6 months was 83·7% (95% CI 69·3-93·2). The proportion of patients treated with methotrexate-vinblastine who had not progressed at 6 months was 45·0% (95% CI 23·1-68·5). The most common grade 3 or 4 adverse events in the pazopanib group were hypertension (n=10, 21%) and diarrhoea (n=7, 15%) and in the methotrexate-vinblastine group were neutropenia (n=10, 45%) and liver transaminitis (n=4, 18%). 11 patients (23%) had at least one serious adverse event related to study treatment in the pazopanib group, as did and six patients (27%) in the methotrexate-vinblastine group. INTERPRETATION: Pazopanib has clinical activity in patients with progressive desmoid tumours and could be a valid treatment option in this rare and disabling disease. FUNDING: GlaxoSmithKline and Novartis.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Toulmonde M, Pulido M, Ray-Coquard I, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019. PMID: 31331699. doi:10.1016/S1470-2045(19)30276-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。